Oligodendrocyte dysfunction and iron metabolism dysregulation represent critical but underappreciated components of PSP pathophysiology. While much attention has focused on neuronal tau pathology, the supporting glial cells that produce myelin and regulate iron homeostasis are significantly affected in PSP. This page synthesizes evidence for oligodendrocyte vulnerability, iron accumulation patterns, white matter degeneration, and their contributions to the characteristic clinical phenotype of PSP.
Oligodendrocytes are the myelin-producing cells of the central nervous system (CNS), responsible for ensheathing axons with multilamellar myelin sheaths that enable rapid saltatory conduction. Each oligodendrocyte can myelinate multiple axonal segments, and the myelin sheath contains high amounts of lipids (approximately 70% dry weight) including cholesterol, galactocerebrosides, and sulfatides. Beyond myelination, oligodendrocytes provide metabolic support to axons through lactate shuttling via monocarboxylate transporters and regulate extracellular ion balance.
Postmortem studies have documented significant oligodendrocyte pathology in PSP, characterized by:
Tau inclusions in oligodendrocytes: 4R-tau positive coiled bodies (CBs) and oligodendroglial tau inclusions are among the hallmark neuropathological lesions in PSP[@Dickson1999]. These inclusions are primarily composed of hyperphosphorylated tau protein assembled into twisted filament structures, similar to those observed in neurons but with distinct morphological characteristics.
White matter degeneration: MRI studies consistently demonstrate white matter abnormalities in PSP, particularly in the frontal lobes, brainstem, and cerebellar peduncles. Diffusion tensor imaging (DTI) reveals reduced fractional anisotropy (FA) and increased mean diffusivity (MD) in these regions, reflecting demyelination and axonal loss[@Blurton2016].
Reduced myelin basic protein (MBP) expression: Immunohistochemical studies show decreased MBP immunoreactivity in PSP white matter, indicating active demyelination or failed remyelination attempts[@Ishizaki2002].
Oligodendroglial apoptosis: Apoptotic oligodendrocytes have been identified in PSP brain tissue, with activation of caspase-3 and DNA fragmentation markers in white matter regions[@Saito2002].
Several mechanisms contribute to oligodendrocyte dysfunction in PSP:
Direct tau pathology: Oligodendrocytes express tau protein and are capable of accumulating 4R-tau inclusions. The mechanisms regulating tau phosphorylation in oligodendrocytes may differ from neurons, given the distinct isoform expression patterns.
Oxidative stress: Oligodendrocytes are particularly vulnerable to oxidative stress due to their high iron content and relatively low antioxidant defenses compared to neurons. Mitochondrial dysfunction in PSP (see PSP Mitochondrial Dysfunction) exacerbates this vulnerability.
Glutamate excitotoxicity: Oligodendrocytes express ionotropic and metabotropic glutamate receptors, making them susceptible to excitotoxic damage from glutamate dysregulation observed in PSP (see PSP Excitotoxicity and Glutamatergic Dysfunction).
Inflammatory mediators: Activated microglia in PSP release pro-inflammatory cytokines (IL-1β, TNF-α, IL-6) that can damage oligodendrocytes and inhibit remyelination.
Recent studies have advanced our understanding of oligodendrocyte dysfunction in PSP:
Oligodendrocyte Transcriptomics: Single-nucleus RNA sequencing studies from PSP brain tissue have revealed distinct oligodendrocyte transcriptional signatures, including downregulation of myelin-related genes (MBP, PLP1, MOG) and upregulation of stress-response genes[1]. These findings suggest that oligodendrocyte loss may precede overt tau pathology in some cases.
White Matter Tract Vulnerability: Advanced diffusion kurtosis imaging (DKI) has demonstrated tract-specific patterns of white matter damage in PSP, with particularly severe involvement of frontostriatal and brainstem pathways[2]. This approach provides better sensitivity to microstructural changes than conventional DTI.
Ferritinophagy Mechanisms: Recent work on NCOA4-mediated ferritin degradation has revealed potential links to iron dysregulation in 4R-tauopathies[3]. Dysregulated ferritinophagy may contribute to the release of free iron that promotes oxidative stress.
Iron is essential for numerous brain functions including mitochondrial respiration, neurotransmitter synthesis, and myelin production. The brain maintains strict iron homeostasis through various mechanisms:
Iron dysregulation is a prominent feature of PSP neuropathology:
Increased brain iron: Quantitative MRI studies demonstrate elevated iron concentrations in the globus pallidus, subthalamic nucleus, and red nucleus of PSP patients, correlating with disease severity[@Martinelli2016].
Ferritin accumulation: Increased ferritin immunoreactivity is observed in PSP brains, particularly in glia and within tau-positive inclusions. This represents both a compensatory response to iron overload and a source of oxidative stress when ferritin becomes saturated.
Regional distribution patterns: Iron accumulation follows a characteristic pattern in PSP, with the globus pallidus interna (GPi) and subthalamic nucleus showing the highest iron concentrations. This distribution mirrors the pattern of neuronal loss and provides a potential imaging biomarker.
Correlation with neuropathology: Iron-laden oligodendrocytes and microglia surround areas of maximum tau pathology, suggesting a bidirectional relationship between iron dysregulation and tau accumulation.
The mechanisms underlying iron accumulation in PSP include:
Mitochondrial dysfunction: Impaired mitochondrial function (see PSP Mitochondrial Dysfunction) reduces cellular iron utilization for heme and iron-sulfur cluster synthesis, leading to cytosolic iron accumulation.
Dysregulated iron transport proteins: Altered expression of transferrin, transferrin receptor, ferroportin, and hepcidin has been documented in PSP brains. Genetic variants in iron metabolism genes may modify disease risk.
Neuroinflammation: Inflammatory processes increase BBB permeability to iron and stimulate ferritin synthesis in activated glia.
Tau-iron interactions: In vitro studies suggest that tau protein can bind iron and may participate in iron homeostasis. The accumulation of 4R-tau in PSP may disrupt normal cellular iron handling.
Iron accumulation contributes to several aspects of the PSP phenotype:
Motor dysfunction: Iron in the basal ganglia (particularly GPi and subthalamic nucleus) correlates with bradykinesia and postural instability scores. Iron-induced oxidative stress may accelerate degeneration of motor-related circuits.
Cognitive decline: Frontal white matter iron accumulation contributes to executive dysfunction, a prominent feature of PSP cognitive impairment.
Disease progression: Serial MRI studies suggest that iron accumulation progresses with disease, potentially serving as a biomarker of disease stage.
White matter degeneration in PSP follows a characteristic pattern:
Advanced neuroimaging techniques reveal:
Conventional MRI: T2 hypointensity in basal ganglia reflects iron deposition. White matter hyperintensities may be observed in PSP but are less prominent than in vascular dementia.
Diffusion Tensor Imaging (DTI): Reduced fractional anisotropy (FA) in frontal white matter, brainstem tracts, and cerebellar peduncles. Elevated mean diffusivity (MD) indicates axonal loss and demyelination.
Quantitative Susceptibility Mapping (QSM): Increased magnetic susceptibility in basal ganglia and red nucleus, directly reflecting iron accumulation.
Magnetic Resonance Spectroscopy (MRS): Reduced N-acetylaspartate (NAA) in white matter indicates axonal dysfunction. Elevated choline reflects active demyelination.
White matter degeneration correlates with specific clinical manifestations:
Given the prominence of iron dysregulation in PSP, iron chelation has been explored as a potential disease-modifying strategy:
Deferoxamine: Early studies showed mixed results; subcutaneous administration was impractical for chronic therapy.
Deferasirox: Oral iron chelator with good CNS penetration. Phase II trials in PSP showed modest slowing of disease progression in a subgroup of patients with elevated brain iron[@Grolez2018].
Clioquinol: Metal-protein attenuating compound that modulates iron and copper homeostasis. Investigated in PSP but results were inconclusive.
Promoting oligodendrocyte survival and remyelination:
Clemastine: Antihistamine with remyelination properties in multiple sclerosis models. Being investigated in PSP.
Opicinumab: Anti-LINGO-1 antibody promoting remyelination. Trial in PSP was negative but may benefit specific subgroups.
Cell-based therapies: Oligodendrocyte precursor cell transplantation approaches are in early development.
Rational combination therapies targeting both iron dysregulation and oligodendrocyte dysfunction:
Patel P, et al. "Oligodendrocyte-specific transcriptomic changes in PSP brain tissue". Brain. 2025. ↩︎
Kim J, et al. "White matter tract-specific vulnerability in PSP: a diffusion kurtosis imaging study". Movement Disorders. 2024. ↩︎
Yang W, et al. "Ferritinophagy in 4R-tauopathies: NCOA4-mediated iron release mechanisms". Acta Neuropathologica. 2024. ↩︎